U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07758218) titled 'Allogeneic iNKT Cell Therapy (agenT-797) After SCT' on Aug. 05.
Brief Summary: The goal of this clinical trial is to learn if agenT-797 is safe to use on people undergoing allogenic hematological stem cell transplantation (SCT). The main questions it aims to answer are:
* Is agenT-797 safe to use?
* What medical problems do participants have when taking agenT-797?
Participants will receive an infusion of agenT-797 about 7 days after their allogenic SCT.
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
Allogenic Stem Cell Transplantation
Myeloid Malignancies
Lymphoid Malignancies
Acute Myeloid Leukemia
Chroni...